Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Lovaza. Every FDA application for this active ingredient: 1 branded and 15 generic.
As of Nov 22, 2026, FDA lists 16 applications for Omega-3-ACID ethyl esters (sold as Lovaza), first approved Nov 10, 2004, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 95 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Lotriga Granular, new ingredientA drug with a new active ingredient indicated for the treatment of hyperlipidaemia. · Takeda Pharmaceutical Company Limited · Sep 28, 2012
Clinical trials
16 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA